Literature DB >> 31165251

[ADAPTHERA-Statewide cross-sectoral care network for patients with early rheumatoid arthritis shows sustained remission in standard care].

A Lauter1, K Triantafyllias2, R Leiß1, C Amberger3, J Engels4, M Hesse5, M Jendro6, J Gilly7, M-L Stadelmann8, W Ziese9, D Wollschläger10, M Dreher1, B Pfeiff2, J Weinmann-Menke1, T Panholzer10, A Schwarting11,12.   

Abstract

BACKGROUND/
OBJECTIVE: The majority of patients in Germany miss out on the necessity of early diagnosis and initiation of therapy for rheumatoid arthritis (RA) caused by considerable structural deficits in the health care system. The challenge is to reconcile the individual demand for the best possible therapy result with a sustainable expenditure of resources.
METHODS: The cross-sectoral regional care network ADAPTHERA aims to improve early RA diagnosis and treatment in Rhineland-Palatinate. The retrospective triage analyses of suspected early onset RA patients was performed by tracing the selection process of all available enquiries (n = 1045). For analysis of the clinical course of the disease, a subset comprising 143 patients with a minimum observation time of 12 months (5 consecutive visits) was available. Clinical and laboratory parameters were collected quarter yearly, self-administered questionnaires were filled out and the treatment was adapted if necessary.
RESULTS: A total of 454 patients were included. The mean waiting time was 23.9 (SD = 18) days. The mean observation period in the subcohort was 29.2 (SD = 12.7) months, with about 50% of the patients presenting within 3 months. Almost 75% of the patients were in remission after 2 years. A sustained remission could be described for 74.8% (6 months) and 53.5% (12 months), respectively. Especially patients with rapid remission induction benefited in terms of longer remissions (p = 0.03). A very early stage of the disease (VERA) was associated with a rarely necessary biologic therapy (p = 0.022). DISCUSSION: The approach of a supply network is not a panacea, but it might improve healthcare for patients with early onset RA. In order to minimize resource utilization, a pinpoint referral and accurate triage of potential cases are crucial.

Entities:  

Keywords:  Early RA; Healthcare; Remission; Waiting time; Window of opportunity

Mesh:

Substances:

Year:  2019        PMID: 31165251     DOI: 10.1007/s00393-019-0653-4

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  25 in total

1.  Delay in receiving rheumatology care leads to long-term harm.

Authors:  Vivian Bykerk; Paul Emery
Journal:  Arthritis Rheum       Date:  2010-12

2.  [Clinical remission in rheumatoid arthritis. Data from the early arthritis cohort study CAPEA].

Authors:  K Albrecht; J Callhoff; E Edelmann; G Schett; M Schneider; A Zink
Journal:  Z Rheumatol       Date:  2016-02       Impact factor: 1.372

3.  Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort.

Authors:  M Vermeer; H H Kuper; H J Bernelot Moens; K W Drossaers-Bakker; A E van der Bijl; P L C M van Riel; M A F J van de Laar
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-08       Impact factor: 4.794

4.  [Memorandum of the German Society for Rheumatology on the quality of treatment in rheumatology - Update 2016].

Authors:  A Zink; J Braun; E Gromnica-Ihle; D Krause; H J Lakomek; W Mau; U Müller-Ladner; J Rautenstrauch; C Specker; M Schneider
Journal:  Z Rheumatol       Date:  2017-04       Impact factor: 1.372

5.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

6.  Diagnostic and therapeutic delay of rheumatoid arthritis and its relationship with health care devices in Catalonia. The AUDIT study.

Authors:  Hèctor Corominas; Javier Narváez; César Díaz-Torné; Georgina Salvador; María Eugenia Gomez-Caballero; Diana de la Fuente; Ester Campoy; Daniel Roig-Vilaseca; Teresa Clavaguera; Rosa Morlà; Vicenç Torrente-Segarra; Xavier Arasa; José Alfredo Gomez-Puerta; Ingrid Möller; Cayetano Alegre; Eduard Graell; Andrés Ponce; María Pilar Lisbona; Carolina Pérez-Garcia; Ramon Fíguls; Elena Sirvent; Violan Poca; Raimon Sanmartí
Journal:  Reumatol Clin       Date:  2015-09-08

7.  Assessing remission in clinical practice.

Authors:  M Mierau; M Schoels; G Gonda; J Fuchs; D Aletaha; J S Smolen
Journal:  Rheumatology (Oxford)       Date:  2007-03-06       Impact factor: 7.580

Review 8.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Authors:  Josef S Smolen; Robert Landewé; Johannes Bijlsma; Gerd Burmester; Katerina Chatzidionysiou; Maxime Dougados; Jackie Nam; Sofia Ramiro; Marieke Voshaar; Ronald van Vollenhoven; Daniel Aletaha; Martin Aringer; Maarten Boers; Chris D Buckley; Frank Buttgereit; Vivian Bykerk; Mario Cardiel; Bernard Combe; Maurizio Cutolo; Yvonne van Eijk-Hustings; Paul Emery; Axel Finckh; Cem Gabay; Juan Gomez-Reino; Laure Gossec; Jacques-Eric Gottenberg; Johanna M W Hazes; Tom Huizinga; Meghna Jani; Dmitry Karateev; Marios Kouloumas; Tore Kvien; Zhanguo Li; Xavier Mariette; Iain McInnes; Eduardo Mysler; Peter Nash; Karel Pavelka; Gyula Poór; Christophe Richez; Piet van Riel; Andrea Rubbert-Roth; Kenneth Saag; Jose da Silva; Tanja Stamm; Tsutomu Takeuchi; René Westhovens; Maarten de Wit; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2017-03-06       Impact factor: 19.103

9.  Time to achieve remission determines time to be in remission.

Authors:  Lydia G Schipper; Jaap Fransen; Alfons A den Broeder; Piet L C M Van Riel
Journal:  Arthritis Res Ther       Date:  2010-05-20       Impact factor: 5.156

10.  Delay in presentation to primary care physicians is the main reason why patients with rheumatoid arthritis are seen late by rheumatologists.

Authors:  K Kumar; E Daley; D M Carruthers; D Situnayake; C Gordon; K Grindulis; C D Buckley; F Khattak; K Raza
Journal:  Rheumatology (Oxford)       Date:  2007-06-19       Impact factor: 7.580

View more
  4 in total

Review 1.  [Experiences and results from Rheuma-VOR].

Authors:  A Schwarting; M Dreher; G Assmann; T Witte; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2019-10       Impact factor: 1.372

Review 2.  [Early recognition and screening consultation: a necessary way to improve early detection and treatment in rheumatology? : Overview of the early recognition and screening consultation models for rheumatic and musculoskeletal diseases in Germany].

Authors:  K Benesova; H-M Lorenz; V Lion; A Voigt; A Krause; O Sander; M Schneider; M Feuchtenberger; A Nigg; J Leipe; S Briem; E Tiessen; F Haas; M Rihl; D Meyer-Olson; X Baraliakos; J Braun; A Schwarting; M Dreher; T Witte; G Assmann; K Hoeper; R E Schmidt; P Bartz-Bazzanella; M Gaubitz; C Specker
Journal:  Z Rheumatol       Date:  2019-10       Impact factor: 1.372

Review 3.  [Physical activity, exercise and nutrition in rheumatism : Adjuvant treatment options for inflammatory-rheumatic diseases].

Authors:  M Dreher; M Kosz; A Schwarting
Journal:  Orthopade       Date:  2019-11       Impact factor: 1.087

4.  [Analysis of referral diagnoses to the rheumatology department].

Authors:  T Hoffmann; P Oelzner; J Böttcher; G Wolf; A Pfeil
Journal:  Z Rheumatol       Date:  2020-03       Impact factor: 1.372

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.